Bifunctional TRPV1 Targeted Magnetothermal Switch to Attenuate Osteoarthritis Progression
Related Experiment Video
Updated: May 8, 2026
Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
Zhongyang Lv1,2, Peng Wang1, Weitong Li3
1Division of Sports Medicine and Adult Reconstructive Surgery, Department of Orthopedic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.
Abstract:
Transient receptor potential vanilloid family member 1 (TRPV1) has been revealed as a therapeutic target of osteoarthritis (OA), the most common deteriorating whole joint disease, by impeding macrophagic inflammation and chondrocytes ferroptosis. However, the clinical application for capsaicin as the TRPV1 agonist is largely limited by its chronic toxicity. To address this issue, we developed a bifunctional controllable magnetothermal switch targeting TRPV1 for the alleviation of OA progression by coupling of magnetic nanoparticles (MNPs) to TRPV1 monoclonal antibodies (MNPs-TRPV1). Under the alternating magnetic field (AMF) stimulation, MNPs-TRPV1 locally dissipated heat, which was sufficient to trigger the opening and activation of TRPV1, and effectively impeded macrophagic inflammation and chondrocyte ferroptosis. This magnetothermal modulation of TRPV1 simultaneously attenuated synovitis and cartilage degeneration in mice incurred by destabilization of medial meniscus surgery, indicating the delayed OA progression. Furthermore, MNPs-TRPV1 with AMF exposure remarkably reduced knee pain sensitivity, alleviated the crippled gait, and improved spontaneous ambulatory activity performance in the mice OA model. Overall, this work provides a potential pathogenesis-based precise OA therapy with temporally and spatially magnetothermal modulation of TRPV1 in a controllable manner.
Insights
This study introduces a novel magnetothermal therapy targeting TRPV1 to treat osteoarthritis (OA). This approach effectively reduces inflammation and cartilage damage, offering a promising new treatment for OA progression.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Immunology
Background:
- Osteoarthritis (OA) is a prevalent degenerative joint disease.
- Transient receptor potential vanilloid family member 1 (TRPV1) is a therapeutic target for OA, but capsaicin's clinical use is limited by toxicity.
- Macrophagic inflammation and chondrocyte ferroptosis contribute to OA pathogenesis.
Purpose of the Study:
- To develop a novel magnetothermal therapy for OA targeting TRPV1.
- To overcome the limitations of existing TRPV1 agonists.
- To precisely control TRPV1 activation for OA treatment.
Main Methods:
- Developed bifunctional magnetic nanoparticles (MNPs) coupled to TRPV1 monoclonal antibodies (MNPs-TRPV1).
- Utilized alternating magnetic field (AMF) stimulation to induce magnetothermal activation of TRPV1.
- Evaluated therapeutic effects in a mouse model of OA induced by destabilization of the medial meniscus (DMM).
Main Results:
- Magnetothermal modulation of TRPV1 effectively impeded macrophagic inflammation and chondrocyte ferroptosis.
- Treatment attenuated synovitis and cartilage degeneration in the OA mouse model.
- AMF exposure of MNPs-TRPV1 reduced knee pain sensitivity, improved gait, and enhanced motor activity.
Conclusions:
- This magnetothermal switch provides a controllable, precise therapeutic strategy for OA.
- Temporally and spatially controlled TRPV1 modulation offers a new pathogenesis-based approach to OA treatment.
- This method shows potential for alleviating OA progression and symptoms.
